HC Wainwright Reaffirms Buy Rating for Vascular Biogenics (NASDAQ:VBLT)

Vascular Biogenics (NASDAQ:VBLT)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Friday, AnalystRatings.com reports. They currently have a $3.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 143.90% from the company’s previous close.

VBLT has been the subject of several other research reports. ValuEngine downgraded shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research downgraded shares of Vascular Biogenics from a “hold” rating to a “sell” rating in a research report on Thursday, August 29th. Finally, Chardan Capital raised shares of Vascular Biogenics from a “neutral” rating to a “buy” rating in a research report on Thursday. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $2.38.

VBLT opened at $1.23 on Friday. The company has a 50-day moving average of $1.27 and a 200-day moving average of $1.26. The company has a market capitalization of $45.57 million, a P/E ratio of -1.98 and a beta of -0.29. Vascular Biogenics has a 1-year low of $0.60 and a 1-year high of $1.90. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.45 and a current ratio of 6.45.

Vascular Biogenics (NASDAQ:VBLT) last released its earnings results on Thursday, November 14th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14). Vascular Biogenics had a negative net margin of 3,021.20% and a negative return on equity of 35.35%. As a group, sell-side analysts expect that Vascular Biogenics will post -0.53 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the stock. Morgan Stanley grew its position in shares of Vascular Biogenics by 6.5% during the 2nd quarter. Morgan Stanley now owns 295,012 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 17,900 shares during the last quarter. Athena Capital Advisors LLC grew its position in shares of Vascular Biogenics by 216.7% during the 2nd quarter. Athena Capital Advisors LLC now owns 35,000 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 23,950 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. grew its position in shares of Vascular Biogenics by 66.7% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 37,500 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 15,000 shares during the last quarter. 5.38% of the stock is owned by institutional investors and hedge funds.

Vascular Biogenics Company Profile

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.

Featured Story: Dividend Reinvestment Plan (DRIP)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.